- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00897130
5-Azacitidine in Low-risk Myelodysplastic Syndromes (MDSs) (MDSAZA0706)
Clinical and Biological Effects of 5-Azacitidine Five Days/Monthly Schedule in Symptomatic Low-risk Myelodysplastic Syndromes (MDSs)
Study Overview
Detailed Description
5-Azacitidine(5-AZA) is the most promising drug for treatment MDSs. When administered at a dose of 75mg/m2/day subcutaneously for 7 days, every 28 days (every month), 5-Aza produces high rates of trilineage responses, reduces the risk of progression to AML in high-risk MDS and improves the QoL. The use of 5-Aza in the earlier phases of MDS could reduce the proliferative advantage of MDS clone and favour the regrowth of normal hematopoiesis. Other doses or schedules could improve its efficacy. Gene expression profile studies in MDS patients who are sensitive or resistant to 5-AZA are lacking and data coming from these studies could be useful to clarify the mechanisms of 5-azacitidine and optimize the therapy.
Objectives of the study
Primary:
- To evaluate the efficacy (hematologic response) and toxicity of 5-Aza five days monthly treatment schedule in patients with low-risk MDS (IPSS 0-INT1)
Secondary:
- To evaluate QoL by the FACT-An questionnaire
- To evaluate time to progression of MDS;
- To evaluate the gene expression profile of MDS patients sensitive or resistant to 5-AZA;
- To evaluate oncostatin M, interleukin-6 and interleukin-11 levels in the responders and non responders.
Azacitidine will be given at a dose of 75mg/sqm subcutaneous daily for 5 consecutive days every 28 days (every month) for a total of 8 courses. 5-Aza dosages will be adjusted as follows:
Patients' care and other medications
- RBC are transfused to maintain a Hb level > 90 g/L, or whenever indicated.
- Platelets are transfused if platelet count is < 20 x 109/L, or whenever indicated.
- EPO is not allowed during the trial time (8 months= 8 courses of 5-AZA therapy)
- Granulocyte or granulocyte-monocyte colony stimulating factor (G-CSF or GM-CSF) are allowed in case of severe neutropenia and/or systemic infection.
- Antibiotics and antifungals per os are given in prophylaxis if neutrophils <0.5 x 109 /L.
- Antibiotics are given i.v. in case of fever (> 38°C for > 24 h) or whenever indicated.
- Antifungals are given i.v. in case of fever persisting for more than 5 days of antibiotics i.v. or whenever indicated.
- Other experimental drugs or agents are not allowed.
- If another experimental drug or agent will be administered, the patient must discontinue the treatment with 5-AZA, and goes off-study.
Definition of Response
The response to treatment will be assessed according to IWG 2006 criteria, as reported by Cheson et al.(28) (Appendix F)
Response criteria for altering natural history of MDS:
- Complete remission (CR) Bone marrow: ≤5% myeloblasts with normal maturation of all cell lines Persistent dysplasia will be notes Peripheral blood: Hgb ≥ 11g/dl, Platelets ≥ 100 x 109/l, Neutrophils ≥ 1.0 x 109/l, Blasts 0%
- Partial remission (PR)
All CR criteria if abnormal before treatment except:
Bone marrow blasts decreased by ≥50% over pretreatment but still >5% Cellularity and morphology not relevant
- Marrow CR Bone marrow ≤ 5% myeloblasts and decrease by ≥ 50% over pretreatment Peripheral blood: if HI response, they will be noted in addition to marrow CR
- Stable disease Failure to achieve at least PR, but no evidence of progression for >8 weeks
- Failure Death during treatment or disease progression characterized by worsening of cytopenias, increase in the percentage bone marrow blasts, or progression to a more advanced MDS FAB subtype than pretreatment.
- Relapse after CR or PR
At least one of the following:
- Return to pretreatment bone marrow blast percentage
- Decrement of ≥ 50% from maximum remission/response levels in granulocytes or platelets
Reduction in Hgb concentration by ≥ 1.5 g/dl or transfusion dependence
Cytogenetic Response
- Complete Disappearance of the chromosomal abnormality without appearance of new ones
- Partial At least 50% reduction of the chromosomal abnormality
- Disease progression For patients with Less than 5% blasts: ≥50% increase in blasts to > 5% blasts 5%-10% blasts: ≥50% increase to >10% blasts 10%-20% blasts: ≥ 50% increase to > 20% blasts 20%-30% blasts: ≥50% increase to >30% blasts Any of the following At least 50% decrement from maximum remission/response in granulocytes or platelets Reduction in Hgb by ≥ 2g/dl Transfusion dependence
Survival
Endpoints:
Overall: death from any cause Event free: failure or death from any cause PFS: disease progression or death form MDS DFS: time to relapse Cause-specific death: death related to MDS
Response criteria for hematologic improvement (HI)
- Erythroid response (HI-E) (pretreatment, <11 g/dl) Hgb increase by ≥1.5 g/dl Relevant reduction on units of RBC transfusion by an absolute number of at least 4 RBC transfusions/8 weeks compared with the pretreatment transfusion number in the previous 8 weeks. Only RBC transfusions given for a Hgb of ≤ 9.0 g/dl pretreatment will count in the RBC transfusion response evaluation
- Platelet response (HI-P)(pretreatment, <100 x 109/l) Absolute increase of ≥ 30 x 109/l for patients starting with >20 x 109/l platelets Increase from < 20 x 109/l to >20 x 109/l and by at least 100%
- Neutrophil response (HI-N) (pretreatment, <1.0 x 109/l) At least 100% increase and an absolute increase > 0.5 x 109/l
Progression or relapse after HI
- At least one of the following:
- At least 50% decrement from maximum response levels in granulocytes or platelets
- Reduction in Hgb by ≥ 1.5 g/dl Transfusion dependence
Quality of Life (QoL) QoL will be assessed by the FACT-An score before treatment and monthly during the study, at the end of each cycle of treatment. The FACT-An questionnaire will be performed as outpatient interviews by one trained nurse The QoL battery, according to FACT-An questionnaire, consists of items including physical, functional, emotional, social spiritual symptoms
Patient evaluation
- Physical examination (at entry and every month).
- Peripheral blood count and differential (at entry and every two weeks).
- Bone marrow biopsy (at entry; at the end of the 4th course; at the end of study-8th course).
- Bone marrow aspirate (at entry; at the end of the 4th course; at the end of study-8th course).
- Cytogenetics (at entry; at end of the 4th course; at the end of study -8th course).
- Blood biochemistry profile (at entry and every month).
- HBV, HCV, HIV (at entry).
- Gene Profile (at entry; at the end of the 4th course; at the end of study-8th course).
- Cytokines, Onc.M, IL6, IL11 (at entry; at the end of the 4th course; at the end of study-8th course).
- FACT-an (at entry; at the end of each course).
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Bologna, Italy
- University of Bologna
-
Brescia, Italy, 25123
- Chair of Haematology, Bone Marrow Transplant Unit
-
Cremona, Italy
- Cremona
-
Genova, Italy
- University of Genova
-
Mantova, Italy
- Mantova
-
Siena, Italy
- University of Siena
-
Udine, Italy
- University of Udine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients with low-risk (IPSS 0-INT1) MDS according to WHO classification, presenting one or more of the followings:
- Symptomatic anemia requiring RBC transfusion supportive therapy previously unresponsive to EPO or not expected to respond to EPO
- Thrombocytopenia requiring platelet transfusion with or without muco-cutaneous haemorrhagic syndrome
- Persistent (> 3 months) absolute neutrophil count less then 1,5 x 109/L, with or without infections, requiring or not myeloid growth factor therapy
- ≥ 18 years old.
- Life expectancy ≥ 3 months.
- ECOG performance Status Grade 0-2.
- Serum bilirubin levels ≤ 1.5 upper limit of the normal (ULN)
- Serum GOT and GPT levels ≤ 2x UNL.
- Creatinine levels ≤ 1.5x UNL.
- Negative serum β-human chorionic gonadotropin (β-HCG) pregnancy test 24 hours prior to beginning of therapy with 5-AZA, for fertile women.
- Written informed consent.
Exclusion Criteria:
- Patients with MDS according to WHO classification with INT-2 or high IPSS risk.
- Life expectancy < 3 months.
- ECOG performance Status Grade > 2.
- Serum bilirubin levels >1.5 upper limit of the normal (ULN).
- Serum GOT and GPT levels > 2 x UNL.
- Creatinine levels >1.5 x UNL.
- Pregnancy or breast feeding.
- Insulin-dependent diabetes and uncontrolled non insulin-dependent diabetes.
- Severe cardiac or pulmonary disease incompatible with the conduction of the protocol.
- Patient with a clear indication to receive long-term anticoagulant therapy.
- Other active hematologic or solid tumors.
- Severe CNS disease.
- Malignant hepatic tumors.
- Hypersensitivity to mannitol or azacitidine.
- No written informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Azacytidine
Azacitidine will be given at a dose of 75mg/sqm subcutaneous daily for 5 consecutive days every 28 days (every month) for a total of 8 courses.
5-Aza dosages will be adjusted.
|
Azacitidine will be given at a dose of 75mg/sqm subcutaneous daily for 5 consecutive days every 28 days (every month) for a total of 8 courses.
5-Aza dosages will be adjusted
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the efficacy (hematologic response) of five days monthly 5-Aza treatment schedule in patients with low-risk MDS (IPSS 0-1).
Time Frame: 36 months
|
36 months
|
To evaluate the toxicity of five days monthly 5-Aza treatment schedule in patients with low-risk MDS (IPSS 0-1).
Time Frame: 36 months
|
36 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the QoL by the FACT-An questionnaire
Time Frame: 36 months
|
36 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Prof Domenico Russo, MD, Chair of Haematology, Brescia University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2007-003943-55
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myelodysplastic Syndrome
-
Brian JonasNational Cancer Institute (NCI); Celgene; Pharmacyclics LLC.CompletedPreviously Treated Myelodysplastic Syndrome | Myelodysplastic Syndrome | Therapy-Related Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic SyndromeUnited States
-
Thomas Jefferson UniversityAbbVieRecruitingMyelodysplastic Syndrome | Recurrent Myelodysplastic Syndrome | Refractory Myelodysplastic SyndromeUnited States
-
Uma BorateRecruitingTherapy-Related Myelodysplastic Syndrome | Secondary Myelodysplastic SyndromeUnited States
-
University Hospital, BrestRecruitingMyelodysplastic Syndromes | Myelodysplastic Syndrome With Isolated Del(5Q) | Myelodysplastic Syndrome With Del(5Q)France
-
Cyclacel Pharmaceuticals, Inc.SuspendedLeukemia | Myelodysplastic Syndrome(MDS)United States
-
TJ Biopharma Co., Ltd.Recruiting
-
National Heart, Lung, and Blood Institute (NHLBI)National Cancer Institute (NCI)RecruitingMyelodysplastic Syndromes (MDS)United States, Israel
-
AbbVieCelgene; Genentech, Inc.CompletedMyelodysplastic Syndromes (MDS)United States, Australia, Germany
-
AbbVieGenentech, Inc.Active, not recruitingMyelodysplastic Syndromes (MDS)United States, Australia, Canada, France, Germany, Italy, United Kingdom
-
The First Affiliated Hospital with Nanjing Medical...UnknownMyelodysplastic Syndromes (MDS)China
Clinical Trials on Azacytidine
-
Swiss Group for Clinical Cancer ResearchCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Biphenotypic LeukemiaUnited States
-
The University of Texas Health Science Center,...RecruitingRecurrent EpendymomaUnited States
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)CompletedRecurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedChronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Acute Myeloid Leukemia With Multilineage Dysplasia | Blasts 20-30 Percent of Bone Marrow Nucleated Cells | Blasts 20-30 Percent of Peripheral Blood White Cells | IPSS Risk Category Intermediate-2United States
-
Uma BorateSumitomo Pharma Oncology, Inc.CompletedAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Lung Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingChronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Recurrent Myeloproliferative NeoplasmUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Leukemia Cutis | Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLLUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAcute Myeloid Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative NeoplasmUnited States